Welcome to BioPharmaceuticals Australia.

BioPharmaceuticals Australia (BPA) is an industry development organisation for Australia’s biopharmaceutical sector. Created by the Queensland State Government in 2007, BPA supports the development of biologic drugs from the pre-clinical stage right through to approved drug products.

Responding to a critical national capability gap in biologic API manufacturing, BPA has delivered a world-class cGMP biopharmaceutical contract manufacturing facility, and partnered with Patheon Biologics (formerly known as DSM Biologics) to operate the facility and deliver contract development and manufacturing solutions tailored to client needs. This new facility was officially opened in October 2013.

In 2014, BPA launched the Biopharmaceutical Development Fund (BDF) - aimed at early-stage clinical and commercial drug developers by encouraging access to this state-of-the-art mammalian cell culture-based infrastructure. Funding is also available for international Patheon client companies wanting to establish local subsidiaries to benefit from Australia’s R&D Tax Incentive and the Clinical Trial Notification (CTN) scheme.

Ten rounds of grant applications have been completed. Five Type 3 and two Type 2 grants have been awarded. Round 10 of the BDF closed end July 2016. A Type 3 Grant was approved under Round 10. Announcement of the outcome awaits grantee approval.

Round 11 is now open :  1 September, 2016 closing 31 October, 2016.

Applications for Type 1 establishment support grants can be made on-line at any time. A Type 1 Grant was awarded to ZZ Biotech earlier in 2016.

BPA's vision is to bring Australia to the forefront of biopharmaceutical development, scale-up and production by providing quality facilities and expertise in conjunction with Patheon Biologics, while promoting the capabilities of Australia’s world-class complementary service providers. 


NOTE: CARTROPHEN queries should be directed to 


BPA is not associated with this product.